Indore pharma unit under fire as inspection flags 216 lapses

Indore: The heartbreaking deaths linked to contaminated Coldrif cough syrup have uncovered serious cracks in pharmaceutical manufacturing standards, leading to a major regulatory crackdown. A pharmaceutical unit in Indore has now been ordered to temporarily stop production after more than 200 deficiencies were found against established standards.

The joint inspection, conducted by the central and state government departments, took place in late September at the pharmaceutical unit operated by a private company in the Sanwer Road Industrial Area, said Chief Medical and Health Officer (CMHO) Dr Madhav Prasad Hasani.

"During the inspection, 216 deficiencies were found against set standards in drug production and other processes. Following this, production at the unit has been halted until further orders. A show-cause notice has also been issued to the private company regarding these deficiencies," he said.